A Leader in Regenerative Medicine with Massive Potential on the Doorstep

BEND, OR / ACCESSWIRE / February 21, 2017 / RepliCel (OTCQB: REPCF) (TSX-V: RP.V) advances in regenerative medicine.

Source: RepliCel

Throughout nature, many animal species have the ability to regenerate parts of their bodies. Examples of this are seen in lizards regrowing their tails, deer regrowing antlers, and sea stars regrowing lost limbs. Physicians and scientists have long dreamed of finding ways to awaken the human body’s ability for regeneration, with hopes of regrowing lost limbs and damaged organs. The search for answers is lead by the interdisciplinary field called regenerative medicine.

Source: MedTech Intellegence

Regenerative medicine takes two approaches to its goal, both in growing replacement tissues in a laboratory environment to be transplanted into the body, and in reawakening the body’s own dormant ability to renew and repair itself.

Over the last couple of decades, there has been a rapid advancement in the general field of medicine, with frequent reports of differing milestones being achieved in the laboratory by researchers. The specialties of developmental and stem cell biology, biochemistry, bioengineering, surgery, and physical sciences, among others, have all made contributions to regenerative medical advancement, where there is a growing sense of optimism for achieving at least some of the field’s goals.

Stem cells have, and are continuing to, provide an ongoing subject of research in regenerative medicine. Unlike most cells in the body, stem cells do more than simply replicate a mirror copy of themselves; they give rise to an entire organism, forming many types of differentiated cells.

Another cell type in the human body being researched are progenitor cells. These cells have the ability to replicate into a limited number of differentiated cell types, based on their tissue of origin.

In humans, stem cells and progenitor cells work together and are responsible for daily tasks like healing and rejuvenating our skin, and repairing our intestinal lining damaged by digestion.

Source: The Pharma Letter

One of the companies working on regenerative therapies is RepliCel (TSXV: RP.V; or the “Company”). RepliCel is focused on developing autologous cell therapies that address conditions linked to a deficit in healthy cells required for normal healing and function. The three therapeutic areas RepliCel’s therapies are designed to treat are chronic tendinosis, damaged and aged skin, and pattern baldness.

Before the end of March, RepliCel anticipates significant milestone announcements in all there of its therapeutic areas:

RCT-01 is the Company’s product for the treatment of chronic tendinosis; a Phase 1/2 clinical trial has recently been completed with the data collected and being analyzed by a third party.

RSC-01 is the Company’s product for the treatment of aging and sub-damaged skin; a Phase 1 clinical trial has recently completed, with quantitative data being compiled currently.

RCH-01 is the Company’s autologous cell therapy for the treatment of pattern baldness in men and women; data from a 5-year safety study, along with 12 and 24-month efficacy data is currently being compiled and analyzed.

With these three major milestone announcements anticipated over the next month and a half, RepliCel has the potential to see a significant change in their market valuation. Should the data all be positive, we believe this would provide for a major catalyst in remarkably growing shareholder value, and price appreciation. Now is the time for your personal due-diligence and evaluating if RP.V represents an investment you don’t want to miss.

SOURCE: Sylva International

ReleaseID: 455497